Share ownership Telix Pharmaceuticals Limited

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:12:56 12/06/2026 BST			5-day change	1st Jan Change
13.60 ^AUD	+0.97%		+2.18%	+21.43%

06-03	Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration; Shares Down 3%	MT
06-02	Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration	MT

Share class: Telix Pharmaceuticals Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	338,778,000	280,812,404 ( 82.89 %)	0	82.89 %

Major shareholders: Telix Pharmaceuticals Limited

Name	Stocks	%	Valuation
Christian Behrenbruch 6.305 %	21,396,941	6.305 %	201 M $
Andreas Kluge 6.092 %	20,675,000	6.092 %	194 M $
Challenger Ltd. (Investment Management) 4.982 %	16,907,315	4.982 %	159 M $
GRAND PHARMACEUTICAL GROUP LIMITED 1.768 %	6,000,000	1.768 %	56 M $
UV-Cap Verwaltungs GmbH 1.437 %	4,878,261	1.437 %	46 M $
Mark Nelson 1.069 %	3,628,750	1.069 %	34 M $
RBC Global Asset Management (Asia) Ltd. 0.7734 %	2,624,809	0.7734 %	25 M $
Netwealth Investments Ltd. 0.7091 %	2,406,576	0.7091 %	23 M $
Landseer Asset Management UK LLP 0.5774 %	1,959,548	0.5774 %	18 M $
BetaShares Capital Ltd. 0.5728 %	1,944,039	0.5728 %	18 M $
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
Fidelity Management & Research Co. LLC 0.1664 %	564,757	0.1664 %	5 M $
Portolan Capital Management LLC 0.1595 %	541,267	0.1595 %	5 M $
Lazard Asset Management LLC 0.0854 %	289,917	0.0854 %	3 M $
Portland Investment Counsel, Inc. 0.0784 %	266,200	0.0784 %	3 M $
Private Advisor Group LLC 0.0514 %	174,415	0.0514 %	2 M $
Integrated Wealth Concepts LLC 0.0484 %	164,397	0.0484 %	2 M $
Raiffeisen Bank International AG (13f Subfiler) 0.0383 %	130,000	0.0383 %	1 M $
Morgan Stanley Capital Services LLC 0.0343 %	116,440	0.0343 %	1 M $
JPMorgan Chase Bank, NA (Investment Management) 0.0169 %	57,348	0.0169 %	540 792 $
Mariner LLC (13F Subfiler) 0.0128 %	43,446	0.0128 %	409 696 $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	14.13%
Institutional	11.83%
Grand Pharmaceutical Group Ltd.	1.77%
Others	0.98%
Telix Pharmaceuticals Ltd.	0.57%
Unknown	70.73%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	14.13%
Australia	7.72%
Hong Kong	2.55%
Germany	1.56%
United States	1.44%
United Kingdom	0.68%
Belgium	0.54%
New Zealand	0.33%
Sweden	0.14%
Canada	0.08%
Austria	0.04%
Ireland	0.04%
Luxembourg	0.01%
Cayman Islands	0.01%
Switzerland	0.01%

Based on 1000 largest holdings

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.

Employees

1,152

Sector

Biotechnology & Medical Research

More about the company